32 results
8-K
EX-99.1
NVRO
Nevro Corp
19 Apr 23
Results of Operations and Financial Condition
5:07pm
and extremely rewarding to work alongside the talented and dedicated individuals who are committed to Nevro’s vision, mission and values. I look forward … and Secondary Education, from Southern Methodist University.
“I am delighted to join Nevro at this exciting time and look forward to furthering its mission
8-K
EX-99.1
NVRO
Nevro Corp
9 Jan 24
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
8:41am
. This was a difficult decision that impacts some of our team members who have been committed to our mission. We appreciate their dedication and contributions … in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary
8-K
EX-99.1
NVRO
Nevro Corp
2 Mar 15
Nevro Appoints Dr. Brad Vale to its Board of Directors
12:00am
and insights have been renowned in Silicon Valley for over two decades and they are great assets as we further our mission of improving the quality of life
8-K
EX-99.1
NVRO
Nevro Corp
1 Aug 22
Other Events
7:11am
treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy
8-K
EX-99.1
NVRO
Nevro Corp
21 Feb 24
Nevro Enters Into Cooperation Agreement With Engaged Capital
4:11pm
for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain
8-K
EX-99.1
hyh6z
1 Dec 23
Nevro Announces Acquisition of Vyrsa™ Technologies
6:07am
8-K
EX-99.1
h50uewe
10 Jan 22
Nevro Announces Preliminary, Unaudited Fourth Quarter and Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million
6:12am
8-K
EX-99.1
o13wo cqczy58g8
5 May 20
Nevro Reports First Quarter 2020 Financial Results
4:16pm
8-K
EX-99.1
py66420l6y kcvky
26 Apr 23
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
4:13pm
8-K
EX-99.1
hu8f 8jwds3s
4 May 22
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance
4:18pm
8-K
EX-99.1
ia8hc 6wkbdbm
1 Aug 23
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
4:10pm
8-K
EX-99.1
1oixouij1x5
23 Feb 22
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
12:00am
8-K
EX-99.1
x9p4adkndzwfj1
1 Nov 23
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
4:07pm
8-K
EX-99.1
up2wbkh
21 Feb 24
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
4:09pm
8-K
EX-99.1
e2d3 8zc8
2 Nov 22
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
4:14pm
8-K
EX-99.1
regjgats1n2ky3abaz7k
7 May 24
Nevro Reports First-Quarter 2024 Financial Results
4:11pm
8-K
EX-99.1
i8u6y
3 Aug 22
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
4:18pm
S-1/A
a3fsu440f geylbaflh
10 Oct 14
IPO registration (amended)
12:00am
S-1
862tfcm6l5f8d 5vx
3 Oct 14
IPO registration
12:00am